112 related articles for article (PubMed ID: 12403054)
1. Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.
Forsberg M; Savolainen J; Järvinen T; Leppänen J; Gynther J; Männistö PT
Pharmacol Toxicol; 2002 Jun; 90(6):327-32. PubMed ID: 12403054
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.
Leppänen J; Savolainen J; Nevalainen T; Forsberg M; Huuskonen J; Taipale H; Gynther J; Männistö PT; Järvinen T
J Pharm Pharmacol; 2001 Nov; 53(11):1489-98. PubMed ID: 11732751
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone.
Savolainen J; Leppanen J; Forsberg M; Taipale H; Nevalainen T; Huuskonen J; Gynther J; Mannisto PT; Jarvinen T
Life Sci; 2000; 67(2):205-16. PubMed ID: 10901288
[TBL] [Abstract][Full Text] [Related]
5. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.
Alqahtani S; Kaddoumi A
Biopharm Drug Dispos; 2015 Dec; 36(9):587-602. PubMed ID: 26295926
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT
J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
[TBL] [Abstract][Full Text] [Related]
7. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Brusa L; Pierantozzi M; Bassi A; Fedele E; Lunardi G; Giacomini P; Stanzione P
Neurol Sci; 2004 Jun; 25(2):53-6. PubMed ID: 15221622
[TBL] [Abstract][Full Text] [Related]
8. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.
Keränen T; Gordin A; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Schultz E; Seppälä L; Wikberg T
Eur J Clin Pharmacol; 1994; 46(2):151-7. PubMed ID: 8039535
[TBL] [Abstract][Full Text] [Related]
10. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
[TBL] [Abstract][Full Text] [Related]
12. Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.
Maltête D; Cottard AM; Mihout B; Costentin J
Clin Neuropharmacol; 2011; 34(1):21-3. PubMed ID: 21164341
[TBL] [Abstract][Full Text] [Related]
13. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.
Li LS; Liu CZ; Xu JD; Zheng LF; Feng XY; Zhang Y; Zhu JX
World J Gastroenterol; 2015 Mar; 21(12):3509-18. PubMed ID: 25834315
[TBL] [Abstract][Full Text] [Related]
14. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.
Keränen T; Gordin A; Koulu M; Scheinin M; Antila S; Sundberg S; Wikberg T
J Neural Transm (Vienna); 1996; 103(6):729-36. PubMed ID: 8836934
[TBL] [Abstract][Full Text] [Related]
15. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
[TBL] [Abstract][Full Text] [Related]
17. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
18. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.
Nissinen E; Nissinen H; Larjonmaa H; Väänänen A; Helkamaa T; Reenilä I; Rauhala P
J Neural Transm (Vienna); 2005 Sep; 112(9):1213-21. PubMed ID: 15614425
[TBL] [Abstract][Full Text] [Related]
19. Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
Brusa L; Bassi A; Lunardi G; Fedele E; Peppe A; Stefani A; Pasqualetti P; Stanzione P; Pierantozzi M
Eur J Neurol; 2004 Sep; 11(9):593-606. PubMed ID: 15379738
[TBL] [Abstract][Full Text] [Related]
20. Clinical advantages of COMT inhibition with entacapone - a review.
Gordin A; Kaakkola S; Teräväinen H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
